STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
114
13F, latest reported quarter
What the filings say about ASPI
Insiders, 180 days
-$4.9M net sold
1 buyer · 6 sellers · 35% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.3M
6 notices
ASP Isotopes insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ASP Isotopes Inc. insiders sold a net $4.9M of stock across 71 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 1, 2026.
The trade is 1.5% of the 1,504,422 shares held after it.
1 other insider sold within 30 days.
114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Kiessling Heather sold about $47.8K of ASPI on Oct 16, 2026; 1 other insider sold within 30 days and 114 funds added in the latest 13F quarter.
14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Sep 8, 2026.
The trade is 1.0% of the 2,225,941 shares held after it.
1 other insider sold within 30 days.
114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO Ainscow Robert sold about $47.6K of ASPI under a 10b5-1 plan on Oct 14, 2026; 1 other insider sold within 30 days and 114 funds added in the latest 13F quarter.
13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Sep 28, 2026.
+8.8% median (+16.7% mean) 90-day return after 8 previous buys.
The trade is 2.2% of the 675,222 shares held after it.
No other insider bought within 30 days.
114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Robert John Andrew bought about $40.2K of ASPI on Sep 30, 2026, the largest insider purchase at the company since 2024; 114 funds added in the latest 13F quarter.
12 earlier Form 4 trades (code P or S) here by this insider (12 buys), the last on Apr 30, 2024.
+8.8% median (+16.7% mean) 90-day return after 8 previous buys.
The trade is 1.2% of the 660,222 shares held after it.
No other insider bought within 30 days.
114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Robert John Andrew bought about $21.6K of ASPI on Sep 28, 2026, the largest insider purchase at the company since 2024; 114 funds added in the latest 13F quarter.
13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Sep 2, 2026.
The trade is 0.4% of the 2,248,441 shares held after it.
2 other insiders sold within 30 days.
114 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO Ainscow Robert sold about $36.2K of ASPI under a 10b5-1 plan on Sep 8, 2026; 2 other insiders sold within 30 days and 114 funds added in the latest 13F quarter.
71 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.9M sold by insiders over 180 days, 114 funds added last quarter, $1.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ASPI
FY Dec 2025
$23.8M
FY Dec 2024
$4.1M
FY Dec 2023
$433.0K
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
$5.1M
Mar 2026
$4.2M
Dec 2025
$16.7M
Sep 2025
$4.9M
Jun 2025
$1.2M
Mar 2025
$1.1M
Dec 2024
$1.2M
Sep 2024
$1.1M
At each fiscal year end
Single quarter
Net margin, TTM
-380.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ASPI
FY Dec 2025
-670.2%
FY Dec 2024
-782.4%
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
-663.5%
Mar 2026
-170.4%
Dec 2025
-380.1%
Sep 2025
-263.7%
Jun 2025
-6,272%
Mar 2025
-767.9%
Dec 2024
-772.4%
Sep 2024
-676.2%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$83.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ASPI
FY Dec 2025
-$47.4M
FY Dec 2024
-$26.4M
FY Dec 2023
-$7.7M
FY Dec 2022
-$7.4M
FY Dec 2022
-$9.2M
Jun 2026
-$27.4M
Mar 2026
-$23.9M
Dec 2025
-$20.2M
Sep 2025
-$12.0M
Jun 2025
-$9.7M
Mar 2025
-$5.5M
Dec 2024
-$5.1M
Sep 2024
-$9.3M
At each fiscal year end
Single quarter
Debt to equity
0.23x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ASPI
FY Dec 2025
0.01x
FY Dec 2024
0.05x
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
0.23x
Mar 2026
0.20x
Dec 2025
0.01x
Sep 2025
0.19x
Jun 2025
0.09x
Mar 2025
0.06x
Dec 2024
0.05x
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.13x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ASPI
FY Dec 2025
-18.38x
FY Dec 2024
-7.02x
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
-1.13x
Mar 2026
-0.90x
Dec 2025
-18.38x
Sep 2025
-1.70x
Jun 2025
-8.27x
Mar 2025
-7.10x
Dec 2024
-7.02x
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-80.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ASPI
FY Dec 2025
-126.8%
FY Dec 2024
-101.0%
FY Dec 2023
-124.8%
FY Dec 2022
-62.5%
FY Dec 2022
-149.2%
Jun 2026
-80.9%
Mar 2026
-95.6%
Dec 2025
-126.8%
Sep 2025
-187.5%
Jun 2025
-552.9%
Mar 2025
-127.9%
Dec 2024
-101.0%
Sep 2024
-115.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-33.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ASPI
FY Dec 2025
-54.0%
FY Dec 2024
-53.2%
FY Dec 2023
-81.4%
FY Dec 2022
-50.4%
FY Dec 2022
-65.9%
Jun 2026
-33.1%
Mar 2026
-46.7%
Dec 2025
-54.0%
Sep 2025
-68.2%
Jun 2025
-105.1%
Mar 2025
-49.8%
Dec 2024
-53.2%
Sep 2024
-57.0%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ASPI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-31.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ASPI
FY Dec 2025
-21.7%
FY Dec 2024
-48.3%
FY Dec 2023
-98.9%
FY Dec 2022
-58.6%
FY Dec 2022
-88.9%
Jun 2026
-31.4%
Mar 2026
-25.6%
Dec 2025
-21.7%
Sep 2025
-31.0%
Jun 2025
-37.6%
Mar 2025
-47.2%
Dec 2024
-48.3%
Sep 2024
-52.9%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ASPI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$149.9M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ASPI
FY Dec 2025
$315.5M
FY Dec 2024
$263.9M
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
$623.3M
Mar 2026
$340.9M
Dec 2025
$315.5M
Sep 2025
$784.2M
Jun 2025
$487.2M
Mar 2025
$284.4M
Dec 2024
$263.9M
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-27.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield ASPI
FY Dec 2025
-8.0%
FY Dec 2024
-8.2%
FY Dec 2023
-8.9%
FY Dec 2022
-13.7%
FY Dec 2022
-17.0%
Jun 2026
-10.7%
Mar 2026
-13.4%
Dec 2025
-8.0%
Sep 2025
-3.6%
Jun 2025
-5.4%
Mar 2025
-8.2%
Dec 2024
-8.2%
Sep 2024
-13.2%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ASPI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2022
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
ASPI ranks highest on growth (98th percentile) and institutional and government (49th), and lowest on risk and compliance (3rd), among Materials peers.
Profitability
10
Inputs
Return on equity-80.9% · 7 pct, sector of 100
Return on assets-33.1% · 15 pct, sector of 120
Return on invested capitalpre-tax loss, no effective tax rate to apply
Return on capital employed-31.4% · 7 pct, sector of 96
Financial health
43
Inputs
Debt to equity0.23x · 79 pct, sector of 104
Cash flow to debt-1.13x · 7 pct, sector of 103
Growth
98
Inputs
Revenue growth, YoY+475.5% · 98 pct, sector of 128
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
35
Inputs
Net Form 4 buying (codes P and S), 180d-$3.7M · 15 pct, sector of 80
Insider buyers, 180d1 · 56 pct, sector of 80
Institutional and government
49
Inputs
Funds adding, latest quarter114 · 49 pct, sector of 118
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
3
Inputs
Short interest, % of float+19.9% · 1 pct, sector of 143
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-K+50.5% · 4 pct, sector of 111
1 not measured: US patents
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ASPI filings, in plain words
Are ASP Isotopes insiders buying or selling ASPI?
In the 180 days to 2026-10-27, ASP Isotopes insiders were net sellers, a net $4.9M: $61.8K of purchases and $4.9M of sales reported on Form 4, by 1 buyer and 6 sellers.
Are there planned insider sales of ASPI?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.3M of stock; the latest, by Heather Kiessling, was filed 2026-10-16.
Read the full summary
In the 180 days to 2026-10-27, ASP Isotopes insiders were net sellers of ASPI, a net $4.9M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 35% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.